GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call November 12, 2024 4:30 PM ET
Company Participants
Max Gadicke - Investor Relations
David Dodd - Chairman and Chief Executive Officer
Mark Reynolds - Chief Financial Officer
Mark Newman - Chief Scientific Officer
Kelly McKee - Chief Medical Officer
John Sharkey - Vice President, Business Development
Conference Call Participants
Jonathan Aschoff - ROTH Capital Partners
James Molloy - Alliance Global Partners
Jason Kolbert - EF Hutton
Vernon Bernardino - H.C. Wainwright
Robert LeBoyer - Noble Capital Markets
Jeffrey Kraws - Crystal Research
Operator
Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Mark Newman, PhD, Chief Scientific Officer; Kelly McKee, MD, MPH, Chief Medical Officer; and John Sharkey, PhD, Vice President, Business Development. [Operator Instructions] As a reminder, this conference is being recorded. At this time, I’m turning the call over to Max Gadicke of Precision AQ.
Max Gadicke
Thank you. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including weather. GeoVax can develop and manufacture its product candidates with desired characteristics in a timely manner and such products will be safe for human use. GeoVax’s vaccines will effectively prevent targeted infections in humans. GeoVax’s product candidates will receive regulatory approvals necessary to be licensed and marketed. GeoVax raises required capital to complete development of its products. There is development of competitive products that may be more effective or easier to use than GeoVax’s products. GeoVax will be able to enter into favorable manufacturing and distribution agreements and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax’ filings with the Securities and Exchange Commission, including those set forth at Risk Factors in GeoVax’s Form 10-K.
It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.
David Dodd
It is a pleasure to welcome everyone to the third quarter 2024 GeoVax corporate update call. Following my comments, Mark Reynolds, our CFO, will provide an update of our financials and then your questions will be addressed. The third quarter included several major events in the development of GeoVax, led by the BARDA Project NextGen award valued at almost $400 million being announced during mid-June. This program is already underway with confirmation that all study sites have been selected as well as our ongoing billings to BARDA. Mark will further discuss this during the financial review. We are delighted to have been paired by BARDA with Allucent as our CRO for the Project NextGen trial as Allucent is our existing CRO supporting our ongoing CM04S1 and recently completed Gedeptin clinical trials.